Fosinopril monotherapy: Relationship between blood pressure reduction and time of administration

Clinical Cardiology

Volumn 16, Issue 4, 1993, Pages 324-330

  Ford, Neville F ^a   Fulmor, I Edgar ^a   Nichola, Peter S ^a   Alpin, Pamela G ^a   Herron, Jarry M ^b  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^b Research Solutions LLC   (United States)

Author keywords

ACE inhibition; dose response; fosinopril; hypertension; through to peak ratio; time effect relationship

Indexed keywords

FOSINOPRIL; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NERVOUSNESS; PRIORITY JOURNAL; PRURITUS; SUPINE POSITION; SYSTOLIC BLOOD PRESSURE; URTICARIA; XEROSTOMIA;

ADULT; AGED; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; FOSINOPRIL; HUMAN; HYPERTENSION; MALE; MIDDLE AGE; PLACEBOS; SINGLE-BLIND METHOD; SUPINE POSITION; TIME FACTORS;

EID: 0027399194     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.4960160407     Document Type: Article

References (25)

1. Blood pressure lowering and renal hemodynamic effects of fosinopril in conscious animal models
2. The effect of fosinopril sodium on cerebral blood flow in moderate essential hypertension
3. Once‐daily fosinopril in the treatment of hypertension
4. 14C‐fosinopril sodium in dogs. In vitro and in vivo studies
5. Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: In vitro and preclinical in vivo pharmacology
6. Clinical pharmacology of fosinopril
7. Disposition of fosinopril sodium in healthy subjects
8. Some problems with antihypertensive drug studies in the context of the new guidelines
9. Angiotensin converting enzyme inhibitors in hypertension
10. Lisinopril: Dose‐peak effect relationship in essential hypertension
11. Lisinopril dose‐response relationship in essential hypertension
12. Chronic dose‐response curve of enalapril in essential hypertensives. An Italian multicenter study
13. Acute dose‐response curve of enalapril in renovascular hypertensives
14. Effective dose range of enalapril in mild to moderate essential hypertension
15. Dose‐response relationship of the angiotensin converting enzyme inhibitor ramipril in mild to moderate essential hypertension
16. Crossover design for the dose determination of an angiotensin converting enzyme inhibitor in hypertension
17. The 24 hour blood pressure responses of hypertensives to a once‐a‐day cilazapril regimen
18. The relationship of dose to the antihypertensive response of verapamil‐sustained release in patients with mild to moderate essential hypertension
19. A placebo‐controlled dose‐response study of felodipine extended release in hypertensive patients
20. Balanced 24‐hour blood pressure control by angiotensin‐converting enzyme inhibitors administered once daily
21. Effect of enalapril at rest, during tilt, static and dynamic exercise in systemic hypertension
22. Assessment of the antihypertensive effect of lisinopril using 24‐hour ambulatory monitoring
23. Diurnal blood pressure in patients with mild‐to‐moderate hypertension treated with once‐daily benazapril hydrochloride
24. Ambulatory blood pressure monitoring: Practical considerations